Cerebral Palsy and Growth Failure at 6 to 7 Years

WHAT’S KNOWN ON THIS SUBJECT: Surviving infants with hypoxic ischemic encephalopathy (HIE) treated with hypothermia have decreased rates of CP in childhood. CP is associated with increased risk of slow growth.

WHAT THIS STUDY ADDS: Term children with HIE who develop moderate/severe CP are at high risk of progressive impaired growth, high rates of cognitive impairment, and rehospitalizations from infancy to school age. Gastrostomy tube placement to facilitate feeds is protective of slow growth.

abstract

OBJECTIVE: To evaluate the association between severity of cerebral palsy (CP) and growth to 6 to 7 years of age among children with moderate to severe (Mod/Sev) hypoxic ischemic encephalopathy (HIE). It was hypothesized that children with Mod/Sev CP would have poorer growth, lower cognitive scores, and increased rehospitalization rates compared with children with no CP (No CP).

METHODS: Among 115 of 122 surviving children followed in the hypothermia trial for neonatal HIE, growth parameters and neurodevelopmental status at 18 to 22 months and 6 to 7 years were available. Group comparisons (Mod/Sev CP and No CP) with unadjusted and adjusted analyses for growth, 10th percentile and z scores by using Fisher’s exact tests and regression modeling were conducted.

RESULTS: Children with Mod/Sev CP had high rates of slow growth and cognitive and motor impairment and rehospitalizations at 18 to 22 months and 6 to 7 years. At 6 to 7 years of age, children with Mod/Sev CP had increased rates of growth parameters, 10th percentile compared with those with No CP (weight, 57% vs 3%; height, 70% vs 2%; and head circumference, 82% vs 13%; \( P < .0001 \)). Increasing severity of slow growth was associated with increasing age (\( P < .04 \) for weight, \( P < .001 \) for length, and \( P < .0001 \) for head circumference). Gastrostomy feeds were associated with better growth.

CONCLUSIONS: Term children with HIE who develop Mod/Sev CP have high and increasing rates of growth <10th percentile by 6 to 7 years of age. These findings support the need for close medical and nutrition management of children with HIE who develop CP.

Pediatrics 2013;132:1–10

AUTHORS: Betty R. Vohr, MD,⁎ Bonnie E. Stephens, MD,⁎ Scott A. McDonald, BS,⁎ Richard A. Ehrenkranz, MD,⁎ Abbot R. Laptook, MD,⁎⁎ Athena Pappas, MD,⁎ Susan R. Hintz, MD,⁎ Seetha Shankaran, MD,⁎ Rosemary D. Higgins, MD,⁎ and Abhik Das, PhD,⁎ on behalf of the Extended Hypothermia Follow-up Subcommittee of the NICHD Neonatal Research Network

⁎Alpert Medical School of Brown University, Providence, Rhode Island; ⁎Women & Infants Hospital of Rhode Island, Providence, Rhode Island; ⁎⁎RTI International, Research Triangle Park, North Carolina; ⁎Department of Pediatrics, Yale University School of Medicine, Yale New Haven Hospital, New Haven, Connecticut; ⁎Department of Pediatrics, Wayne State University, Children’s Hospital of Michigan and Hutzel Women’s Hospital, Detroit, Michigan; ⁎Department of Pediatrics, Stanford University School of Medicine, Lucile Packard Children’s Hospital, Palo Alto, California; ⁎National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland; and ⁎⁎RTI International, Rockville, Maryland

KEY WORDS: encephalopathy, hypoxia-ischemia, hypothermia, cerebral palsy, growth

ABBREVIATIONS

CI—confidence interval
CP—cerebral palsy
DCC—data coordinating center
GMFCS—gross motor function classification system
HC—head circumference
HIE—hypoxic ischemic encephalopathy
HT—height
LT—length
MDI—Mental Developmental Index
Mod/Sev—moderate to severe
NICHD—Eunice Kennedy Shriver National Institute of Child Health and Human Development
NRN—Neonatal Research Network
OR—odds ratio
PDI—Psychomotor Development Index
WT—weight

Dr Vohr conceptualized and designed the study, drafted the original manuscript, and approved the final manuscript before it was submitted; Drs Stephens, Ehrenkranz, Shankaran, Higgins, Pappas and Hintz reviewed and revised the manuscript and approved the final manuscript as submitted; and Mr McDonald and Dr Das carried out the data analysis, reviewed and revised the manuscript, and approved the final manuscript as submitted.

(Continued on last page)
Infants who experience moderate or severe hypoxic ischemic encephalopathy (HIE) are at increased risk of neurodevelopmental disability and moderate to severe (Mod/Sev) cerebral palsy (CP). Slow growth is more common in children with Mod/Sev CP. Decreased growth velocity in children with CP may be related to decreased oromotor coordination with suboptimal nutritional intake secondary to impaired chewing and swallowing, recurrent aspiration, chronic reflux, inadequate provision of required nutritional intake, increased caloric expenditure due to the excessive muscle contraction in spasticity for children with ambulatory CP, and the possibility of growth hormone deficiency. In addition, comorbidities of CP, including gastroesophageal reflux and aspiration, are associated with slow growth and increased risk of rehospitalization. Vigilance regarding growth of children with feeding difficulties goes beyond the concern of body size alone. Linear growth is correlated with head/brain growth and subsequent neurodevelopmental outcome in infants and young children. In addition, inadequate nutritional intake is associated with weakness of respiratory musculature, impaired cough reflex, and pneumonia. Growth is an excellent indicator of the overall health of children and there are currently no data available on the growth outcomes of Mod/Sev HIE survivors in the era of hypothermia therapy. The over-arching goal of this secondary analysis is to use data collected from birth to 6 to 7 years within a cohort of term Mod/Sev HIE survivors with Mod/Sev CP or without CP (No CP) to examine growth, cognitive development, and rehospitalization rates.

**METHODS**

The study was a secondary analysis of prospectively collected data from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Neonatal Research Network (NRN) Whole Body Cooling trial for neonatal HIE conducted between July 2000 and May 2003. Inclusion criteria for the trial included a gestational age of \( \geq \)36 weeks, specific physiologic and/or clinical criteria, and the presence of Mod/Sev encephalopathy. The participants in this secondary analysis were the school-aged survivors evaluated at 18 to 22 months and 6 to 7 years with growth data at birth discharge, 18 to 22 months, and 6 to 7 years. Detailed demographic information and medical history were obtained at follow-up.

**Growth Parameters**

WT was obtained by using a horizontal scale at birth, discharge, and 18 to 22 months, and an upright scale at 6 to 7 years. Standard procedures were used. Recumbent LT was used at birth, discharge, and 18 to 22 months and upright stature at 6 to 7 years with a permanently affixed stadiometer or upright scale. Horizontal measurement was obtained with a stadiometer for children who were unable to stand. The World Health Organization growth standards were used to determine percentiles, velocities, and \( z \) scores at birth, discharge, 18 to 22 months, and at 6 to 7 years; the 2000 Centers for Disease Control and Prevention growth charts were used at 6 to 7 years.

**Neurodevelopmental Assessments**

Comprehensive assessments of neurologic status and development were obtained at 18 to 22 months and 6 to 7 years of age. Examiners were trained annually to reliability on all evaluations, and were masked to the intervention. At 18 to 22 months, children were assessed with the Bayley Scales of Infant Development II and a Mental Developmental Index (MDI) and Psychomotor Development Index (PDI) were calculated. The Bayley has a mean ± SD score of 100 ± 15. A score <70 is 2 SD below the mean and a score <50 is 3 SD below the mean. Intelligence at 6 to 7 years was assessed with the Wechsler Preschool and Primary Scale of Intelligence III for children up to age 7 years 3 months and the Wechsler Intelligence Scale for Children IV for children older than 7 years 3 months or Spanish speaking. These tests derive a full-scale IQ with a mean ± SD of 100 ± 15. A score <70 is 2 SD below the mean and a score <55 is 3 SD below the mean. CP was defined as a nonprogressive central nervous system disorder with abnormal muscle tone in at least 1 extremity and abnormal control of movement and posture that interfere with age-appropriate activities. Severity of CP was classified by using the gross motor function classification system (GMFCS). Mod/Sev CP was defined as GMFCS levels V (n = 16), IV (n = 2), III (n = 4), and II (n = 1). There were no children with mild CP defined as GMFCS level I. The No CP group was defined as any child with no CP. At each visit, parents were queried regarding number of rehospitalizations. Hospitalizations reported for time 1 occurred.
between discharge and 18 months and for time 2 were cumulative between discharge and 6 to 7 years.

The study protocol was approved by the institutional review boards of all participating NICHD NRN sites and parental consent was obtained.

**Statistical Analyses**

Data were collected at participating NICHD NRN sites and were transmitted to Research Triangle Institute, the data coordinating center (DCC), which analyzed the data. Birth and hospital data were combined with data from the 2 follow-up assessments. Preliminary unadjusted comparisons were made by using $t$ tests for continuous variables and Fisher’s exact tests for categorical variables.

The specific aims and hypotheses were examined by using the following parallel approaches. For specific aim 1, longitudinal analysis of growth trajectories over time was performed for the 4 assessment time points: birth, discharge, 18 to 22 months, and 6 to 7 years. Separate longitudinal models accounting for repeated measures were developed for each growth parameter, which were treated as continuous variables/outcomes. Factors of principal interest, such as Mod/Sev CP, were entered into these models as time-varying covariates assessed separately at 18 months and 6 to 7 years. Other time-varying factors included in the models were age, public insurance, gastrostomy, and rehospitalization (the latter 3 were assessed only at 18 months and 6 to 7 years). Models also adjusted for interaction between CP and age (to allow for changes in effect of CP over time), treatment group (hypothermia or control), level of encephalopathy at random assignment (moderate or severe), gender, and birth weight (except in the model for WT).

For specific aim 2, multiple logistic regression analyses were performed to determine the independent predictors of suboptimal growth (WT, HT, and HC below the 10th percentile) at 6 to 7 years of age. Factors of principal interest (eg, Mod/Sev CP, treatment group, level of HIE) and other covariates were added to the logistic regression models in a sequential manner, in a series of 3 time-oriented models. The first model consisted of neonatal covariates (gender, birth weight, cooling, and level of HIE), the second model added information at 18 to 22 months (Mod/Sev CP at 18 to 22 months: public health insurance between discharge and 18 to 22 months, rehospitalization from discharge to 18 to 22 months, and gastrostomy feedings at 18 to 22 months), and the third model replaced the 18- to 22-month variables with 6- to 7-year versions of those variables. Center was entered as a random effect in all of the logistic regression models.

Given the sample size and the number of covariates that were deemed necessary to adjust for, we used stepwise backward selection in both the longitudinal and logistic regression models to develop a relatively parsimonious model for each outcome, by using a $P$ value cutoff of .15 to eliminate covariates from the final models that were not significantly related to the outcome in the presence of other covariates.

**RESULTS**

**Derivation of Study Cohort**

Subjects were the surviving children of the NRN whole-body cooling trial who were assessed at both 18 to 22 months and 6 to 7 years of age. Growth parameters were available for 65 of 70 children treated with hypothermia and 50 of 52 children in the control group (Fig 1).

The study cohort ($n = 115$) was compared with the cohort that was lost to follow-up or had no growth parameters ($n = 25$) on multiple maternal and infant characteristics (data not shown). The only significant group difference identified was percentage with intra-partum fetal heart rate decelerations (growth cohort [73%] versus survivors with no growth data [92%]; $P = .04$).

**Cohort Characteristics**

The cohort included 23 children with Mod/Sev CP and 92 children with No CP in the comparison group. Children with Mod/Sev CP were more likely to have had severe encephalopathy ($P = .009$); more days of ventilation ($P = .053$); require postdischarge oxygen
(P = .007), gavage feeding (P = .002), or gastrostomy feeding (P = .03); and receive anticonvulsant medication (P = .001) (Table 1). At 18 to 22 months among the Mod/Sev children, 3 continued to require oxygen treatment, the number with a gastrostomy had risen to 10 (45%), and only 14% were reported to independently feed themselves compared with 95% with No CP; P < .0001. They were more likely to have had a rehospitalization compared with the No CP children (59% vs 25%; P = .0001) compared with the No CP group. The rehospitalization rate continued to be higher for Mod/Sev CP versus No CP (18 [78%] vs 23 [25%]; P < .0001). More than 1 reason was often given for the hospitalization; most frequent for the children with Mod/Sev CP were pneumonia (61%), surgery/tendon releases (56%), reflux/dehydration (44%), seizures (56%), and failure to thrive (22%). The percentage of children with severe motor and cognitive impairment with 87% having a Bayley II MDI and Bayley II PDI <50. At 6 to 7 years, the percentage of children in the Mod/Sev group with gastrostomy feeds had risen to 52%. They were more likely to be receiving physical therapy (87% vs 7%; P < .0001) and occupational therapy (83% vs 9%; P < .0001) than the No CP group. The rehospitalization rate continued to be higher for Mod/Sev CP versus No CP (18 [78%] vs 23 [25%]; P < .0001). More than 1 reason was often given for the hospitalization; most frequent for the children with Mod/Sev CP were pneumonia (61%), surgery/tendon releases (56%), reflux/dehydration (44%), seizures (56%), and failure to thrive (22%). The percentage of children with severe motor and cognitive impairment with 87% having a Bayley II MDI and Bayley II PDI <50. At 6 to 7 years, the percentage of children in the Mod/Sev group with gastrostomy feeds had risen to 52%. They were more likely to be receiving physical therapy (87% vs 7%; P < .0001) and occupational therapy (83% vs 9%; P < .0001) than the No CP group. The rehospitalization rate continued to be higher for Mod/Sev CP versus No CP (18 [78%] vs 23 [25%]; P < .0001). More than 1 reason was often given for the hospitalization; most frequent for the children with Mod/Sev CP were pneumonia (61%), surgery/tendon releases (56%), reflux/dehydration (44%), seizures (56%), and failure to thrive (22%). The percentage of children with

**TABLE 1** Neonatal, Postdischarge, 18- to 22-Month, and 6- to 7-Year Characteristics of the Cohort

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mod/Sev CP Yes</th>
<th>No CP</th>
<th>P*</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>23</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>Prenatal care, n (%)</td>
<td>21 (91)</td>
<td>87 (95)</td>
<td>.63</td>
</tr>
<tr>
<td>Medicaid, 18 mo, n (%)</td>
<td>15 (68)</td>
<td>43 (47)</td>
<td>.10</td>
</tr>
<tr>
<td>Medicaid, 7 y, n (%)</td>
<td>18 (78)</td>
<td>50 (54)</td>
<td>.96</td>
</tr>
<tr>
<td>Maternal education &lt;12 y, birth, n (%)</td>
<td>4 (24)</td>
<td>27 (38)</td>
<td>.28</td>
</tr>
<tr>
<td>Level of encephalopathy moderate, n (%)</td>
<td>13 (57)</td>
<td>77 (84)</td>
<td>.009</td>
</tr>
<tr>
<td>Level of encephalopathy severe, n (%)</td>
<td>10 (43)</td>
<td>15 (16)</td>
<td>.68</td>
</tr>
<tr>
<td>Cooled, n (%)</td>
<td>9 (39)</td>
<td>56 (61)</td>
<td>.10</td>
</tr>
<tr>
<td>Gestational age, M±SD</td>
<td>38 ± 1.75</td>
<td>39.9 ± 1.53</td>
<td>.08</td>
</tr>
<tr>
<td>Small for gestational age, n (%)</td>
<td>2 (9)</td>
<td>11 (12)</td>
<td>.89</td>
</tr>
<tr>
<td>Days ventilation, M±SD</td>
<td>7.74 ± 7.99</td>
<td>4.23 ± 4.44</td>
<td>.053</td>
</tr>
<tr>
<td>Days hospitalization, M±SD</td>
<td>20.6 ± 11.6</td>
<td>17.0 ± 15.4</td>
<td>.30</td>
</tr>
<tr>
<td>Home therapy prescribed at discharge, n (%)</td>
<td>3 (14)</td>
<td>0 (0)</td>
<td>.007</td>
</tr>
<tr>
<td>Oxygen</td>
<td>3 (14)</td>
<td>0 (0)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Gavage tube feeding</td>
<td>6 (27)</td>
<td>3 (3)</td>
<td>.002</td>
</tr>
<tr>
<td>Gastrostomy feeding</td>
<td>4 (18)</td>
<td>3 (3)</td>
<td>.03</td>
</tr>
<tr>
<td>Anticonvulsant medication</td>
<td>16 (73)</td>
<td>29 (33)</td>
<td>.001</td>
</tr>
<tr>
<td>18–22 mo, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxygen</td>
<td>3 (14)</td>
<td>0 (0)</td>
<td>.007</td>
</tr>
<tr>
<td>Gastrostomy feeding</td>
<td>10 (45)</td>
<td>1 (1)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Independently feeds self</td>
<td>3 (14)</td>
<td>86 (95)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Rehospitalization by 18–22 mo</td>
<td>13 (59)</td>
<td>23 (25)</td>
<td>.004</td>
</tr>
<tr>
<td>Mod/Sev CP</td>
<td>22 (96)</td>
<td>0 (0)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Bayley PDI &lt;70</td>
<td>22 (96)</td>
<td>6 (7)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Bayley PDI &lt;50</td>
<td>20 (87)</td>
<td>3 (3)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Bayley MDI &lt;70</td>
<td>22 (96)</td>
<td>7 (8)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Bayley MDI &lt;50</td>
<td>20 (87)</td>
<td>0 (0)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>6–7 y, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastrostomy feeding</td>
<td>12 (52)</td>
<td>0 (0)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Physical therapy</td>
<td>20 (87)</td>
<td>6 (7)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Occupational therapy</td>
<td>19 (83)</td>
<td>8 (9)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Rehospitalization by 6–7 y</td>
<td>18 (78)</td>
<td>23 (25)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Wechsler Full Scale IQ &lt;70</td>
<td>22 (96)</td>
<td>9 (10)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Wechsler Full Scale IQ &lt;55</td>
<td>20 (87)</td>
<td>2 (2)</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

* P values from Fisher’s exact test or z test (GA, days ventilation, days hospitalization).
incorporating 6- to 7-year follow-up information, rehospitalization at 6 to 7 years was significantly associated with an HC <10th percentile (OR = 4.99; CI = 1.23–20.20; \( P = .03 \)). Backward covariate selection removed level of HIE from most models, and even when retained it was not statistically significant (\( P > .1 \)).

Table 4 shows the longitudinal modeling conducted for growth z scores to examine increasing age effects on severity of growth restriction. In all of the models, Mod/Sev CP had a significant negative effect in predicting WT, LT/HT, and HC z scores, which increased by 0.96 and 0.90, respectively, for each kilogram increase in birth weight (both \( P < .0001 \)); use of a gastrostomy was associated with better growth of WT and LT but not head growth.

Statistical interactions were tested between Mod/Sev CP and age on z scores for WT, HT, and HC, as shown in Table 5. These models allow for the effect of Mod/Sev CP to change over time, and, conversely, for the effect of age to be different for the 2 study groups, which is a pattern suggested by Fig 2. The interaction between age and CP was significant for WT (\( P = .001 \)), LT (\( P = .002 \)), and HC (\( P = .0001 \)). Children with Mod/Sev CP had z scores that deviated farther from the mean of the reference population with increasing age, indicating greater severity of growth restriction over time. In contrast, children with No CP had evidence of catch-up growth.

The significant interaction between Mod/Sev CP and age prompted us to conduct a subgroup analysis among only the children with Mod/Sev CP. When the longitudinal regression model was run for the subset with Mod/Sev CP (Table 6), gastrostomy was beneficial for WT z score (adjusted mean difference in z score = 1.02; \( P = .006 \)), and the hypothermia treatment group was beneficial for LT/HT z score (adjusted mean difference in z score = 0.63; \( P = .01 \)).

**DISCUSSION**

This study cohort represents a select homogeneous group of children who were diagnosed with Mod/Sev HIE by using strict criteria with follow-up conducted by examiners trained to reliability in all components of the assessment. Our findings supported our hypothesis that term children with Mod/Sev HIE who develop Mod/Sev CP have significantly slower growth and increasing severity of suboptimal growth between birth and 6 to 7 years compared with children with No CP. This is consistent with other reports showing trajectories of increasing rate and severity of growth failure for children with Mod/Sev CP. Infant and child characteristics provide insight into factors associated with slow growth. During the neonatal hospitalization, infants in the Mod/Sev CP group had greater illness severity reflected by level of HIE and longer duration of ventilatory support. At discharge, they had high rates of

**FIGURE 2**
Association of Mod/Sev CP at 6 to 7 years with WT, LT/HT, and HC <10th percentile.
TABLE 2 Growth Parameters at Birth, Discharge, 18 to 22 Months, and 6 to 7 Years

| Characteristic | Mod/Sev CP Yes | No CP | P
|----------------|---------------|-------|---
| n              | 23            | 92    |  
| Birth          |               |       |  
| WT, M±SD       | 3.29 ± 0.54   | 3.41 ± 0.63 | .38  
| WT <10th%      | 5 (15%)       | 9 (10%) | .70  
| WT z score, M±SD| −0.05 ± 1.14  | 0.17 ± 1.28 | .45  
| LT, M±SD       | 50.5 ± 3.68   | 50.9 ± 3.81 | .54  
| LT <10th%      | 4 (18%)       | 7 (8%)  | .22  
| LT z score, M±SD| 0.54 ± 1.88   | 0.71 ± 1.50 | .65  
| HC, M±SD       | 33.9 ± 1.43   | 34.3 ± 1.50 | .36  
| HC <10th%      | 4 (17%)       | 8 (9%)  | .27  
| HC z score, M±SD| −0.15 ± 1.17  | 0.04 ± 1.21 | .49  

Discharge

| Characteristic | Mod/Sev CP Yes | No CP | P
|----------------|---------------|-------|---
| WT, M±SD       | 3.48 ± 0.64   | 3.62 ± 0.77 | .42  
| WT <10th%      | 8 (33%)       | 18 (20%) | .15  
| WT z score, M±SD| −0.86 ± 1.31  | −0.40 ± 1.21 | .11  
| LT, M±SD       | 51.5 ± 3.44   | 52.3 ± 3.43 | .39  
| LT <10th%      | 6 (33%)       | 15 (18%) | .20  
| LT z score, M±SD| −0.52 ± 1.82  | −0.001 ± 1.48 | .19  
| HC, M±SD       | 34.9 ± 1.63   | 35.3 ± 1.98 | .43  
| HC <10th%      | 9 (45%)       | 21 (24%) | .10  
| HC z score, M±SD| −1.00 ± 1.63  | −0.42 ± 1.43 | .12  

18–22 mo

| Characteristic | Mod/Sev CP Yes | No CP | P
|----------------|---------------|-------|---
| WT, M±SD       | 9.54 ± 1.97   | 11.8 ± 1.62 | <.0001  
| WT <10th%      | 13 (59%)      | 2 (2%)  | <.0001  
| WT z score, M±SD| −1.48 ± 1.36  | 0.47 ± 0.95 | <.0001  
| LT, M±SD       | 80.2 ± 5.84   | 82.7 ± 5.77 | .10  
| LT <10th%      | 9 (47%)       | 13 (15%) | .004  
| LT z score, M±SD| −1.53 ± 1.42  | −0.30 ± 1.08 | <.0001  
| HC, M±SD       | 44.3 ± 2.21   | 47.7 ± 1.63 | <.0001  
| HC <10th%      | 16 (73%)      | 6 (7%)  | <.0001  
| HC z score, M±SD| −2.04 ± 1.87  | 0.57 ± 1.09 | <.0001  

6–7 y

| Characteristic | Mod/Sev CP Yes | No CP | P
|----------------|---------------|-------|---
| WT, M±SD       | 20.5 ± 8.48   | 25.5 ± 5.50 | .0004  
| WT <10th%      | 12 (57%)      | 3 (3%)  | <.0001  
| WT z score, M±SD| −1.26 ± 1.84  | 0.54 ± 1.05 | <.0003  
| LT, M±SD       | 113.4 ± 7.37  | 121.6 ± 6.05 | <.0005  
| LT <10th%      | 14 (70%)      | 2 (2%)  | <.0001  
| LT z score, M±SD| −1.52 ± 1.68  | 0.23 ± 1.01 | .0002  
| HC, M±SD       | 47.8 ± 2.77   | 51.9 ± 1.72 | <.0001  
| HC <10th%      | 18 (82%)      | 12 (13%) | <.0001  

P values are from t test or Fisher's exact test (<10th percentile). Data for measurements and z scores are presented as mean ± SD, and parameter <10th percentile.

Feeding and respiratory difficulties resulting in rehospitalization were reported at both follow-up visits. After discharge, an additional 8 children had gastrostomy and 5 had fundoplication surgery. Families may be reluctant to accept the surgical intervention until growth restriction is severe or until aspiration becomes a concern. Our findings confirm the importance of gastrostomy feeds to support nutritional intake and growth for children with Mod/Sev CP. This is consistent with the study of gastrostomy placement among children with CP by Sullivan et al34 in which they showed clinically significant increases in WT 12 months after gastrostomy placement.

Because in the main trial hypothermia treatment was associated with medical needs, including continued oxygen requirement, gavage or gastrostomy feeds, and anticonvulsant medications.
a decreased rate of Mod/Sev disability among surviving infants, we included hypothermia in our regression models. In the model restricted to only the children with Mod/Sev CP, hypothermia was associated with a 0.63 increase in z score for HT at ages 6 to 7. Because this was identified in a single regression model, the significance of the finding remains unclear.

Neurocognitive outcomes of the children with Mod/Sev CP were poor, with high rates of severe cognitive (87%) and motor impairment (87%) at both 18 months and at 6 to 7 years, and high rates of hospitalizations for seizure management and surgical procedures related to CP. These severe neurologic and cognitive impairments suggest this population of term Mod/Sev HIE survivors with Mod/Sev CP is a vulnerable population. The areas of brain injury noted in the infants with Mod/Sev encephalopathy have recently been described in the Total Body Hypothermia, NICHD, and Infant Cooling Evaluation trials, respectively.35–37 Areas of injury include the basal ganglia, thalamus, anterior and posterior internal capsule, white matter cortical areas, and watershed areas of infarction.

Strengths of our study include longitudinal data from newborn to 6 to 7 years on term HIE infants who participated in a randomized trial. Limitations include lack of nutritional intake data, missing growth data on 7 children, secondary analysis not powered to evaluate growth outcomes, and use of a standard protocol for assessing linear growth. Segmental measurements of extremities have been found to be more reliable in obtaining accurate linear measurements for children with severe CP and contractures.38,39 Finally, the infants who were randomly assigned to the control group had a higher mortality rate,7 hence information on the surviving infants may be subject to bias. Our study provides evidence of early and progressive growth failure among term infants with Mod/Sev HIE who develop Mod/Sev CP. Placement of a gastrostomy was beneficial for growth, suggesting that earlier intervention for feeding difficulties in this population may provide added benefit.18–23 The combination of Mod/Sev CP, poor growth, associated comorbidities, and increased use of health care presents a significant public health problem. In 2006, children with neurologic impairment in the United States accounted for 29% (US$12.0 billion) of hospital charges within children’s hospitals.40 Our findings support the need for close medical and nutritional management of children with HIE who are diagnosed with CP.

ACKNOWLEDGMENTS

Data collected at participating sites of the NICHD NRN were transmitted to RTI International, the DCC for the network, which stored, managed, and analyzed the data for this study. On behalf of the NRN, Dr Das (DCC Principal Investigator) and Mr McDonald (DCC Statistician) had full access to all the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis.

We are indebted to our medical and nursing colleagues and the infants and their parents who agreed to take part in this study. The following investigators, in addition to those listed as authors, participated in this study:


NRN Steering Committee Chairs: Alan H. Jobe, MD, PhD, University of Cincinnati (2005–2006); Michael S. Caplan, MD, University of Chicago, Pritzker School of Medicine (2006–present).

Alpert Medical School of Brown University and Women & Infants Hospital of Rhode Island (U10 HD27904): Theresa M. Leach, MEd, CAES; William Oh, MD; Angelita M. Hensman, RN, BSN; Lucy Noel; Victoria E. Watson, MS, CAS.

Case Western Reserve University, Rainbow Babies & Children’s Hospital (U10 HD21364, M01 RR80): Michele C. Walsh, MD, MS; Avroy A. Fanaroff, MD; Deanne E. Wilson-Costello, MD; Nancy Bass, MD; Harriet G. Friedman, MA; Nancy S. Newman, BA, RN; Bonnie S. Siner, RN.
Cincinnati Children's Hospital Medical Center and University of Cincinnati Hospital (U10 HD27853, M01 RR8084): Kurt Schibil, MD; Edward F. Donovan, MD; Kimberly Yolton, PhD; Kate Bridges, MD; Jean J. Steichen, MD; Barbara Alexander, RN; Cathy Grisby, BSN, CCRC; Holly L. Mincey, RN, BSN; Jody Hessling, RN; Teresa L. Gratton, PA.

Duke University School of Medicine, University Hospital, Alamance Regional Medical Center, and Durham Regional Hospital (U10 HD40492, M01 RR30): Ronald N. Goldberg, MD, C. Michael Cotten, MD, MHS; Ricki F. Goldstein, MD; Kathryn E. Gustafson, PhD; Kathy J. Auten, MS; Katherine A. Foy, RN; Kimberley A. Fisher, PhD, FNP-BC, IBCLC; Sandy Grimes, RN, BSN; Melody B. Lohmeyer, RN, MSN.

Emory University, Grady Memorial Hospital, and Emory University Hospital Midtown (U10 HD27851, M01 RR39): Barbara J. Stoll, MD; David P. Carlton, MD; Lucky Jain, MD; Ira Adams-Chapman, MD; Ann M. Blackwelder, RN, BS, MS; Ellen C. Hale, RN, BS, CCRC; Sobha Fritz, PhD.

NICHHD: Linda L. Wright, MD; Elizabeth M. McClure, MEd; Stephanie Wilson Archer, MA.

Indiana University, University Hospital, Methodist Hospital, Riley Hospital for Children, and Wishard Health Services (U10 HD27856, M01 RR750): Brenda B. Poindexter, MD, MS; James A. Lemons, MD; Anna M. Dusick, MD, FAAP; Diana D. Appel, RN, BSN; Jessica Bissey, PsyD, HSP; Dianne E. Herron, RN; Lucy C. Miller, RN, BSN, CCRC; Leslie Richard, RN, Leslie Dawn Wilson, BSN, CCRC.

RTI International (U10 HD36790): W. Kenneth Poole, PhD; Jeanette O'Donnell Auman, BS; Margaret Cunningham, BS; Jane Hammond, PhD; Betty K. Hastings; Jamie E. Newman, PhD, MPH; Carolyn M. Petrie Huitema, MS, Scott E. Schaefer, MS; Kristin M. Zaterka-Baxter, RN, BSN.

Stanford University and Lucile Packard Children’s Hospital (U10 HD27880, M01 RR70): Krisa P. Van Meurs, MD; Susan R. Hintz, MD, MS; Epi; David K. Stevenson, MD, M. Bethany Ball, BS, CCRC; Maria Elena De Anda, PhD. University of Alabama at Birmingham Health System and Children’s Hospital of Alabama (U10 HD34216, M01 RR32):
REFERENCES


### Cerebral Palsy and Growth Failure at 6 to 7 Years


*Pediatrics*; originally published online September 9, 2013; DOI: 10.1542/peds.2012-3915

<table>
<thead>
<tr>
<th>Updated Information &amp; Services</th>
<th>including high resolution figures, can be found at: /content/early/2013/09/04/peds.2012-3915</th>
</tr>
</thead>
<tbody>
<tr>
<td>Permissions &amp; Licensing</td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: /site/misc/Permissions.xhtml</td>
</tr>
<tr>
<td>Reprints</td>
<td>Information about ordering reprints can be found online: /site/misc/reprints.xhtml</td>
</tr>
</tbody>
</table>
Cerebral Palsy and Growth Failure at 6 to 7 Years
Betty R. Vohr, Bonnie E. Stephens, Scott A. McDonald, Richard A. Ehrenkranz,
Abbot R. Laptook, Athina Pappas, Susan R. Hintz, Seetha Shankaran, Rosemary D.
Higgins and Abhik Das
Pediatrics; originally published online September 9, 2013;
DOI: 10.1542/peds.2012-3915

The online version of this article, along with updated information and services, is
located on the World Wide Web at:
/content/early/2013/09/04/peds.2012-3915